Suggested remit: To appraise the clinical and cost effectiveness of osimertinib within its marketing authorisation as maintenance treatment of EGFR mutation-positive locally advanced or unresectable non-small-cell lung cancer (NSCLC) which has not progressed after platinum based chemoradiation.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6223
Provisional Schedule
- Expected publication:
- 28 August 2025
Project Team
- Project lead
- Thomas Feist
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Liverpool Reviews and Implementation Group, University of Liverpool
Stakeholders
- Companies sponsors
- AstraZeneca (osimertinib)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- EGFR Positive
- Roy Castle Lung Cancer Foundation
- Professional groups
- Association of Cancer Physicians
- Association of Respiratory Nurse Specialists
- British Thoracic Oncology Group
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- AstraZeneca (durvalumab)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health – Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Comittee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 June 2025 | Committee meeting |
| 04 April 2025 | Due to operational constaints at NICE although the topic remains a single technology appraisal (STA) it will be discussed by the highly specialised technologies (HST) committee in on 19 June 2025. |
| 30 October 2024 | Invitation to participate |
| 10 July 2024 - 07 August 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6223 |
| 10 July 2024 | In progress. Scoping commencing |
| 14 March 2024 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late October 2024 when we will write to you about how you can get involved. |
| 26 January 2024 | Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes. |
| 31 July 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-July 2024. |
| 16 December 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
| 28 November 2022 | Topic selection |
For further information on our processes and methods, please see our CHTE processes and methods manual